{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:30:16Z","timestamp":1761611416642},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Hangzhou ACEA Pharmaceutical Research Co., Ltd."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jpba.2017.02.057","type":"journal-article","created":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T07:16:53Z","timestamp":1488698213000},"page":"205-214","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Development of an UPLC\u2013MS\/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients"],"prefix":"10.1016","volume":"139","author":[{"given":"Weicong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2016","key":"10.1016\/j.jpba.2017.02.057_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jpba.2017.02.057_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2015.02.029","article-title":"Pharmacogenomics and targeted therapy of cancer: focusing on non-small cell lung cancer","volume":"754","author":"Haghgoo","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpba.2017.02.057_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.02.057_bib0020","first-page":"809","article-title":"Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M","volume":"4","author":"Costa","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.jpba.2017.02.057_bib0025","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1590\/1414-431X20144099","article-title":"Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data","volume":"47","author":"Jorge","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.jpba.2017.02.057_bib0030","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2017.02.057_bib0035","first-page":"5","article-title":"Advances on EGFR mutation for lung cancer","volume":"1","author":"Metro","year":"2012","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.jpba.2017.02.057_bib0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cca.2015.01.039","article-title":"EGFR T790M resistance mutation in non small-cell lung carcinoma","volume":"444","author":"Denis","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2017.02.057_bib0045","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2017.02.057_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40880-015-0029-3","article-title":"Parallel phase 1 clinical trials in the US and in China: accelerating the test of AC0010 in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance","volume":"34","author":"Xu","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.jpba.2017.02.057_bib0055","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0281","article-title":"AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients","volume":"15","author":"Xu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpba.2017.02.057_bib0060","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1517\/14656566.2015.1094056","article-title":"Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer","volume":"16","author":"Metro","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpba.2017.02.057_bib0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40261-016-0411-1","article-title":"Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer","volume":"36","author":"Ricciuti","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jpba.2017.02.057_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2016.09.032","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS method for quantification of kukoamine B in human plasma: application to a clinical pharmacokinetic study","volume":"132","author":"Wang","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.02.057_bib0075","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Food and Drug Administration (FDA)","year":"2013"},{"key":"10.1016\/j.jpba.2017.02.057_bib0080","series-title":"Guideline Bioanalytical Method Validation","author":"European Medicines Agency (EMA)","year":"2012"},{"key":"10.1016\/j.jpba.2017.02.057_bib0085","series-title":"Guideline on Bioanalytical Method Validation, China Pharmacopeia (version 2015). Part 2","first-page":"363","author":"China Food and Drug Administration (CFDA)","year":"2015"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517302224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517302224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T04:41:31Z","timestamp":1538023291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708517302224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":17,"alternative-id":["S0731708517302224"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.057","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an UPLC\u2013MS\/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}